Case number 1:23-cv-00750
AbbVie Inc. v. Lupin Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Dec 22, 2023 | 9 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,542,239 B2. (Attachments: # 1 Order)(nms) (Entered: 12/22/2023) (0) |
| Dec 21, 2023 | N/A | CASE CLOSED per entry of D.I. 170 in Lead Civil Action 22-1423-RGA-JLH. (nms) (Entered: 12/21/2023) (0) |
| Oct 10, 2023 | N/A | CORRECTING ENTRY: The Answer (D.I. 9) and the Disclosure Statement (D.I. 10) filed on 10/6/2023, have been removed from the docket. All papers are to be filed in Lead Civil Action 22-1423-RGA-JLH only (see D.I. 7 ) (nms) (Entered: 10/10/2023) (0) |
| Sep 13, 2023 | 8 | STIPULATION TO EXTEND TIME Defendants Lupin Limited and Lupin Pharmaceuticals, Inc. to answer, move, or otherwise respond to the Complaint to October 6, 2023 - filed by AbbVie Inc.. (Tigan, Jeremy) (Entered: 09/13/2023) (2) |
| Sep 13, 2023 | N/A | SO ORDERED, re 8 STIPULATION and Proposed Order (*Reset Answer Deadlines: Lupin Limited answer due 10/6/2023; Lupin Pharmaceuticals, Inc. answer due 10/6/2023). Signed by Judge Richard G. Andrews on 9/13/2023. (lah) (Entered: 09/13/2023) (0) |
| Aug 16, 2023 | 7 | SO ORDERED Granting (D.I. 12 in 23-cv-374-RGA; D.I. 13 in 23-cv-607-RGA; D.I. 6 in 23-cv-750-RGA; D.I. 12 in 23-cv-448-RGA; D.I. 9 in 23-cv-684-RGA; D.I. 113 in 22-cv-1423-RGA-JLH; D.I. 13 in 23-cv-00470-RGA) Stipulation and Proposed Order Concerning Amended Complaint and Consolidation (see Order for further details). Signed by Judge Richard G. Andrews on 8/16/2023. Associated Cases: 1:22-cv-01423-RGA-JLH et al.(nms) (Entered: 08/16/2023) (7) |
| Aug 10, 2023 | 6 | STIPULATION and Proposed Order Concerning Amended Complaint and Consolidation, AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibits A-G, # 3 Supplemental ANDA form, # 4 Supplemental ANDA form, # 5 Supplemental ANDA form, # 6 Amended Patent Report, # 7 Exhibit 2)(Tigan, Jeremy) Modified on 8/10/2023 (nms). (Entered: 08/10/2023) (0) |
| Jul 12, 2023 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 07/12/2023) (0) |
| Jul 10, 2023 | 1 | Complaint* (1) |
| Jul 10, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jdb) (Entered: 07/11/2023) (3) |
| Jul 10, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date of Expiration of Patent: 7/23/2039.Thirty Month Stay Deadline: 1/23/2026. (jdb) (Entered: 07/11/2023) (1) |
| Jul 10, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,542,239 B2. (jdb) (Entered: 07/11/2023) (1) |
| Jul 10, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by AbbVie Inc. (jdb) (Entered: 07/11/2023) (1) |
| Jul 10, 2023 | N/A | No Summons Issued. (jdb) (Entered: 07/11/2023) (0) |
